FY2024 Earnings Estimate for RAPT Issued By Leerink Partnrs

RAPT Therapeutics, Inc. (NASDAQ:RAPT) – Equities researchers at Leerink Partnrs cut their FY2024 EPS estimates for RAPT Therapeutics in a research note issued to investors on Monday, November 11th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of ($2.72) per share for the year, down from their prior forecast of ($2.52). The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.73) per share. Leerink Partnrs also issued estimates for RAPT Therapeutics’ Q4 2024 earnings at ($0.58) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at ($1.54) EPS, FY2027 earnings at ($1.19) EPS and FY2028 earnings at ($1.33) EPS.

Several other research analysts have also issued reports on RAPT. UBS Group dropped their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a research report on Monday, September 9th. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday. Stifel Nicolaus restated a “hold” rating and set a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday. HC Wainwright reiterated a “neutral” rating on shares of RAPT Therapeutics in a research report on Tuesday. Finally, Wells Fargo & Company cut their price objective on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $13.00.

RAPT Therapeutics Stock Performance

Shares of RAPT stock opened at $1.28 on Thursday. The firm has a fifty day moving average of $1.96 and a 200-day moving average of $3.05. The stock has a market cap of $44.68 million, a price-to-earnings ratio of -0.48 and a beta of 0.33. RAPT Therapeutics has a 52-week low of $1.25 and a 52-week high of $27.35.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in RAPT Therapeutics by 21.2% in the 1st quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock valued at $22,386,000 after acquiring an additional 436,629 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of RAPT Therapeutics during the first quarter valued at approximately $97,000. EntryPoint Capital LLC acquired a new stake in shares of RAPT Therapeutics in the first quarter valued at approximately $161,000. Redmile Group LLC raised its position in RAPT Therapeutics by 80.6% in the 1st quarter. Redmile Group LLC now owns 662,398 shares of the company’s stock worth $5,948,000 after purchasing an additional 295,622 shares during the last quarter. Finally, Kingdon Capital Management L.L.C. lifted its holdings in RAPT Therapeutics by 55.3% during the 1st quarter. Kingdon Capital Management L.L.C. now owns 1,500,000 shares of the company’s stock worth $13,470,000 after buying an additional 534,172 shares in the last quarter. 99.09% of the stock is owned by institutional investors.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.